Context Therapeutics Inc.

During the three months ended September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act)adopted orterminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in the SEC’s rules).

CTIM-76 Lonza License Agreement Amendment

On November 7, 2022, we entered into a License Agreement (the “CTIM-76 Lonza License Agreement”) with Lonza Sales AG (“Lonza”) related to CTIM-76. On November 3, 2025, we amended the CTIM-76 Lonza License Agreement (the

“First CTIM-76 License Amendment”) with Lonza to clarify the intent of certain provisions and to update certain of the licensed rights described in the appendices to the CTIM-76 Lonza License Agreement.

CT-202 Lonza License Agreement

On November 3, 2025, we entered into a License Agreement (the “CT-202 Lonza License Agreement”) with Lonza related to CT-202 in connection with the Development and Manufacturing Services Agreement between Lonza, Lonza AG and the Company, dated as of November 7, 2022 and as amended on January 9, 2025. Under the terms of the CT-202 Lonza License Agreement, to the extent Lonza's technology is incorporated into CT-202, Lonza granted the Company a non-exclusive license to use certain proprietary Lonza intellectual property and systems for the Company to develop, manufacture and commercially exploit CT-202.

We shall pay certain royalties and annual payments in respect of the manufacturing and sale of CT-202, which amounts shall be determined by the party manufacturing CT-202 and include a potential annual payment of less than $500,000 and a royalty on net sales in a range between 0% and a low single digit percentage. The royalty payments and annual payments would be reduced in certain circumstances, including should the valid claims for any such patent rights not exist in the country in which CT-202 is being sold, and the royalty payments would expire upon the later of the expiration of the licensed patents in the country in which CT-202 is being sold, the expiration of the licensed patents in the country in which CT-202 is being manufactured, and ten years from the first commercial sales of CT-202 in such country of sale.

The CT-202 Lonza License Agreement continues until terminated, and we or Lonza may terminate the CT-202 Lonza License Agreement for uncured material breaches or insolvency of the other party. We can unilaterally terminate the CT-202 Lonza License Agreement with prior written notice to Lonza, and Lonza can also unilaterally terminate the CT-202 Lonza License Agreement upon certain actions by the Company.

The CT-202 Lonza License Agreement also contains customary representations, warranties, indemnification and other obligations of the Company and Lonza.

The foregoing descriptions of the First CTIM-76 License Amendment and the CT-202 Lonza License Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the First CTIM-76 License Amendment and the CT-202 Lonza License Agreement, which are Exhibits 10.1 and 10.2, respectively, to this Quarterly Report on Form 10-Q and are incorporated herein by reference.